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Donor
Annulus
diameter [mm]
Valve/Frame
size [mm]
Pull force
towards
LV {N]
Pull force
towards
aorta [N]
Donor 1 33-36 F26 8.6 27
Donor 2 27-29 F29 461* 37.82*
Donor 3 21.5 V23 28 13
Donor 4 25-27 V23 12 3.8
Donor 5 21-23 V26 272* 272*
1* Suture broke due to excessive pull force
2* Stopped pulling at this force without any observed dislodgement.
Key: F – Frame,V- Valve N-Newtons
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comdifferences were observed in PPAR, post-procedural mean gradient, cerebrovascular
events, and 30-day or 1-year VARC-2 composite endpoints between the 2 groups.
Finally, at a median follow-up period of 429 days (IQR 208 - 730), Kaplan-Meier
curves reported no signiﬁcant differences in long-term all-cause (17.8% vs. 23%; Log
Rank p ¼ 0.210) and cardiovascular mortality (13.3% vs. 17.6%; Log Rank p ¼
0.256).
Conclusions: According to our results, direct MCV implantation is safe and effective,
with outcomes comparable to MCV implantation with PBAV. However it was
associated with a higher need of VBPD.
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Background: Transcatheter aortic valve implantation (TAVI) is an emerging treat-
ment option for inoperable or high risk patients. Low implantation (over 8mm) has
been frequently implicated with moderate or severe paravalvular aortic regurgitation
(PVR). However, it has not been evaluated the effect of high implantation on the
outcome of the procedure. The purpose of this study is to assess whether high im-
plantation affects the short- and long-term outcome of the procedure.
Methods: Consecutive patients who underwent TAVI were evaluated. Echocardio-
graphic parameters were recorded before the procedure, at discharge of the patient and
during one month- and one year- follow-up. Permanent pacemaker implantation (PPI),
one month- as well as one year- mortality were recorded according to VARC criteria.
ID was deﬁned as the distance both from the native coronary cusp (NCC) and the left
coronary cusp(LCC) to the deepest edge of the deployed bioprosthesis in the left
ventricle using an ofﬂine program. The patients were separated into two groups ac-
cording to the ID. Group I included all patients with normal (4-8 mm) or low im-
plantation (>8mm) and Group II included those with high (0-4 mm) or over the
annulus implantation(distance from either LCC or NCC < 0 mm).
Results: One hundrend eighty six consecutive patients (815.5 years, 103 males)
who underwent TAVI were recorded.In Group I, peak gradientat discharge (178 vs.
144 mmHg, p< 0.01) and mean gradient at discharge (94 vs. 7,53,5 ,p¼0.02)
was signiﬁcantly higher comparing to Group II, while there was no difference among
two groups during one month- and one year- follow up. Furthermore, the percentage
of patients with need for PPI after TAVI, was signiﬁcantly greater in Group I
comparing to Group II (45.6% vs. 2.9% , p¼0.03). Similarly, one year- all cause
mortality was higher in Group I (13,7% vs. 0%, p¼0.03) while one year- cardio-
vascular as well as one month- and in-hospital mortality did not differ among two
groups.
Conclusions: In conclusion, high implantation seems to have a positive effect on
short- and long-term outcome of the procedure.
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Background: Bicuspid aortic valve (BAV) is the most common congenital heart
disease and may lead to aortic valve stenosis. Although Transcatheter Aortic Valve
Replacement(TAVR) emerged as an alternative therapy in high-risk patients with
tricuspid aortic valve stenosis, presence of a stenotic BAV is often considered a
contraindication, due to its unique anatomy and increased risk of periprocedural
complications. We aimed to assess the feasibility and outcomes of TAVR in high-risk
patients with bicuspid aortic valve stenosis.
Methods: The study is a prospective, single-centre registry of patients with BAV
stenosis treated with TAVR. Periprocedural safety, hemodynamic and clinical
outcome was observed during patient follow-up.
Results: Of 130 high-risk patients with severe aortic stenosis who underwent
TAVR from January 2009 to May 2014 in our centre, 15 (12.5%) patients had
documented BAV. Patients were aged 769 years (range 56-90), with mean Lo-
gistic EuroScore I of 2011%, all in New York Heart Association functional class
III. The mean aortic valve area was 0.760.36 cm2, mean gradient was 45.315.1
mmHg and mean LVEF was 50.512.4%. The procedure was performed using
transfemoral access in 13 (87%), transaortic in 1 (6.5%) and transapical in 1
(6.5%) patient. Medtronic CoreValve prosthesis was implanted in 9 (60%) and
Edwards Sapien XT in 6 (40%) patients. TAVI procedure was successful in 13
patients (87%). Major adverse events according to the second Valvular AcademicB218 JACC Vol 64/11/Suppl B j SepResearch Consortium deﬁnitions were present in 2 patients: 1 periprocedural death
(Edwards Sapien XT 29) and 1 periprocedural stroke (Medtronic CoreValve 26).
Importantly, both complications were related to prosthesis dislocation from the
bicuspid aortic valve annulus. Postprocedural aortic valve mean gradient was 82
mmHg and AVA 1.40.4 cm2. After a mean follow-up of 1312 months (range
1-39) no further adverse events occurred. All survivors remained in NYHA class I
or II.
Conclusions: Our initial experience suggests TAVI using CoreValve and Sapien XT
prostheses in high risk patients with stenotic bicuspid aortic valve is feasible, leading
to good short term hemodynamic and clinical improvement.
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Background: TAVR success requires both anchoring and sealing in the native aortic
valve complex. These two processes may be unique and not interdependent. Using
undersized TAVR device we tested the mechanism of TAVR anchoring
Methods: Five cadaveric hearts with severe aortic stenosis were imaged with
CT-scanning. An annular diameter was measured, and a calcium score was assigned.
The hearts were pressurized such that SAPIEN 3 (Edwards Lifesciences) valves and
frames (implants) could be delivered and deployed. Two endoscopes were positioned,
one at the apex and the other in the ascending aorta, to enable visibility. Depending on
annulus size, an S3 valve or frame was chosen to be implanted under ﬂuoroscopic and
endoscopic guidance such that the implant would be smaller than the annulus
currently recommended per Edwards instructions for use (IFU), Strings were attached
at three points both at the inﬂow and outﬂow portions of the Edwards implants to pull
and measure the force required to move the prosthesis. The implants were deployed at
discrete inﬂation volume until the frame initially engaged with the native leaﬂets.
Dimensions were measured, and pull forces were applied in both the LV and aortic
directions until the implant demonstrated movement . A gauge attached to the strings,
measured dislodgement forces.
Results: See table
Conclusions: High pull forces are required to displace undersized TAVR valves in the
absence of annular interaction with the prosthesis indicating that: anchoring is at the
native leaﬂet level and that anchoring and sealing may be two distinct processes.TCT-747
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Background: Transcatheter aortic valve intervention (TAVI) is a recognized life-
saving treatment for those who are at high risk for conventional aortic valve surgery.
The ﬁnancial cost of a TAVI “pathway” from the time of referral to the time of
hospital discharge was assessed.
Methods: Consecutive patients (n¼46) who underwent TAVI between February
2012 and December 2013 at Hammersmith Hospital, London, UK were
included in this retrospective study. The analysis included costs of outpatient
appointment, investigations prior to the procedure, the TAVI procedure as well as
post-procedural costs including the cost of pacemaker implantation. NHS
tariff costs were used for the assessment. Comparison of the costs incurred
following implantation of the Edwards and CoreValve bioprostheses was also
performed.tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
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III/IV (95.7%). The transfemoral route was the most common access site (78.3%) with
an equal number of patients receiving the Edwards and CoreValve bioprostheses. The
largest expense was the TAVI procedure and the subsequent in-hospital stay,
excluding intensive care unit stay, ($52,052). The average “pathway” cost per patient
up to the point of discharge was $860879613. This included clinic appointments at
the specialized TAVI clinic, investigations, the procedure itself as well as the sub-
sequent hospital stay. Comparison between the 2 valves suggested that the cost was
slightly higher for CoreValve as compared to Edwards ($8905811663 vs.
$831177564, p¼0.05) although this was due to the higher cost of the CoreValve and
the more frequent need for permanent pacemaker associated with this. No signiﬁcant
differences were noted between the 2 valves when these 2 factors were excluded
($6320811324 vs. 596927564, p¼0.26).
Conclusions: Although expensive, TAVI is justiﬁed by the improvements in long-
term mortality in inoperable patients as compared to medical therapy alone. Increasing
competition, improvements in valve technology and other procedural parameters are
likely to make TAVI cheaper. Future trials should prospectively assess the “pathway”
costs for both TAVI and conventional surgery, rather than just procedural costs.
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Background: The purpose of this study was to demonstrate the feasibility and pro-
cedural outcomes with the Colibri Transcatheter Aortic Heart Valve. The Colibri Heart
valve is the lowest proﬁle (14Fr) ﬁrst dry valve. It comes completely crimped and
sterilized ready for use from the package to the patient. Currently available heart
valves, for surgical or catheter implantation, require rinsing of the chemicals they
contain and crimping of the valve (TAVI cases) before implantation. We describe here
the outcome of the ﬁrst in human cohort of implants of the Colibri Heart Valve up to
15 months of follow up.
Methods: After the initial successful clinical and hemodynamics results of the ﬁrst
Colibri Transcatheter Aortic Valve Implant (CTAVI), we performed, under a
compassionate use protocol, four additional consecutive CTAVI patients with severe
aortic stenosis who were not surgical candidates. All patients were symptomatic,
NYHA class 3-4, and had preserved ejection fraction. The ﬁve patients’ average aortic
valve mean gradient (MG) pre-procedure was 53 mmHg and the average aortic valve
area (AVA) of 0.71 cm2. All cases were accessed transfemoral after surgical exposure
of the artery. Balloon aortic valvuloplasty was performed before the CTAVI
implantation.
Results: The valve was implanted successful in the orthotopic position in all cases
using rapid ventricular pacing and ﬂuoroscopic guidance. The MG decreased to 8.4
mmHg and the AVA increased to 2.2 cm2, there were no transvalvular regurgitations,
no need for permanent pacemaker and no stroke. One case had mild paravalvular
insufﬁciency. All patients were discharged home ambulatory . Follow-up for 15
months (n1), 7 months (n1) and 3 months (n3) with excellent clinical outcomes
NYHA 1, no evidence of major adverse events and maintenance of mean gradients of
10 mmHg and AVA of 2.2 cm2.
Conclusions: The Colibri HV implantations, the world’s ﬁrst pre-package, sterilized,
dry valve and ready for use 14Fr system is feasible and safe. The beneﬁcial clinical
and hemodynamic outcomes are persistent up to 15 months with low gradients and
large aortic valve area. This low proﬁle valve opens the opportunity to treat patients
with small femoral arteries.
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Background: Direct ﬂow medical (DFM) prosthesis is a non-metallic, repositionable
and retrievable bioprosthetic valve which has never been previously compared with
current status of care. In this study we sought to compare the procedural and 30-day
outcome after transcatheter aortic valve implantation (TAVI) with three different
prostheses: DFM vs. Medtronic CoreValve (MCV) vs. Edwards Sapien XT (ES).
Methods: Twenty-one consecutive patients treated with DFM for severe aortic ste-
nosis were matched to an equal sample of patients undergoing TAVI with MCV and
ES (1:1:1 propensity score-matching). Primary end-point was 30-day safety, deﬁnedJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Vaaccording to the VARC criteria as the composite of all-cause mortality, stroke, life-
threatening bleeding, stage-2 or -3 acute kidney injury, coronary artery obstruction
requiring intervention, major vascular complications or repeat procedures for valve-
related dysfunction. Secondary end-points were: post-TAVI transaortic gradient
reduction; and device success.
Results: Baseline comparison between patients treated with different prostheses
revealed no signiﬁcant demographic and clinical characteristics. Patients treated with
DFM had higher safety rates, with respect to MCV and ES (respectively 90.5% vs.
42.9% vs. 57.1%; p¼0.004) at 30-day follow up. Post-TAVI transaortic gradient
reduction was similar for DFM, MCV and ES subgroups (8.35.2 mmHg vs. 5.33.7
mmHg vs. 5.65.1mmHg, respectively; p¼0.155). Likewise, devise success did not
differ signiﬁcantly (100% vs. 95.2% vs. 90.5%, respectively, p ¼0.21). In the pooled
binary logistic regression analysis, DFM prosthesis was independent predictor of early
safety (DFM vs. MCV: OR 11.2, 95% CI 1.9-66.7, p¼0.008; and DFM vs. ES: OR
5.8, 95% CI 1.0-35.7, p¼0.056).
Conclusions: DFM prosthesis has a better safety proﬁle when compared to MCV and
ES. Device success and short-term outcome rates were comparable between patients
treated with DFM, MCV or ES.
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Background: Renin angiotensin system (RAS) blockade with angiotensin-converting
enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) have survival
beneﬁt in heart failure. Persistent heart failure after surgical aortic valve replacement
(SAVR) for severe aortic stenosis (AS) is associated with poor outcome. Data are
lacking on the impact of RAS blockade after SAVR for severe AS.We sought to
investigate the impact ofassociation between RAS blockade therapy on and outcomes
following SAVR for severe AS.
Methods: Patients prescribed ACEI/ARB after SAVR for severe AS between 1991
and 2010, with at least 2 reﬁlls 90 days apart and at least 6 month follow up in our
health system constituted the RAS blockade group (n¼741) and those not prescribed
ACEI/ARB were the untreatedcontrol group (n¼1,011). Unadjusted and propensity
matched analyses (treatedcase: control untreated ratio of 1:1 yielding 594 matched
pairs) were performed. Primary outcome was survival after SAVR. Secondary end
points were changes in left ventricular mass index (LVMI), left ventricular ejection
fraction (LVEF) and left atrial (LA) size after SAVR.
Results: A total of 562 deaths occurred over a mean follow up of 6.3  4.1 years.
Overall unadjusted estimated survival at 1, 5 and 10 years was 99%, 90% and 69% in
the RAS group compared to 99%, 81% and 53% respectively in the non-RAS group
(p< 0.0001). Among propensity matched patients, estimated survival at 1, 5 and 10
years remained signiﬁcantly higher in the RAS group compared to non-RAS group
(99%, 90% and 71% vs. 96%, 78% and 49%, respectively p< 0.0001). When stratiﬁed
by concomitant CABG, survival remained signiﬁcantly higher in the RAS group
(unadjusted and propensity matched, p< 0.0001). For the matched cohorts, on
echocardiographic analysis there were no signiﬁcant group differences between the
RAS and non RAS groups with respect to change in LVMI (p¼0.37),LVEF(p¼0.67)
and LA size (p¼0.43) after SAVR
Conclusions: RAS blockade is associated with an improved survival in patients
following AVR for severe AS. Therapy with ACEI/ARB should be considered in
patients after AVR for AS if proven beneﬁcial in a randomized controlled trial.
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Background: CT analyses of patients with aortic stenosis reveal that in many patients
the aortic annulus is eccentric. Therefore, the aim of this study was to assess the
performance of the transapical Jenavalve in an in vitro hydrodynamic and durability
test model comparing circular and eccentric aortic annulus geometry.
Methods: Based on CT-data from 123 consecutive TAVI-patients, a mean annulus
eccentricity (eccentricity¼short diameter/long diameter) of 0.84 was determined.
Two models of aortic roots with valve leaﬂets, one circular in shape and one dis-
playing an eccentricity of 0.84 were created with oriﬁce areas corresponding to a
circular 27mm annulus. Valve hydrodynamics were evaluated at different ﬂow rateslvular disease - Aortic: TAVR B219
